Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 14, 2025—Bio-Rad Laboratories has received the EU quality management systems certificate under IVDR regulation (EU) 2017/746, enabling the CE-IVDR marking of 40 Exact Diagnostics infectious disease molecular quality controls.
Webinar presenter Pranil K. Chandra, DO, Senior Vice President, Chief Genomics Officer, PathGroup, explores pathogenic gene fusions as oncogenic drivers and actionable biomarkers in precision oncology, focusing on NRG1 fusions.
March 11, 2025—Beckman Coulter Diagnostics announced that its DxC 500i clinical analyzer received FDA 510(k) clearance.
March 2025—Leica Biosystems announced the next iteration in its staining and coverslipping portfolio, the HistoCore Chromax Workstation. The HistoCore Chromax WS includes a reagent management system and features graphical, touchscreen interfaces. It is for in vitro diagnostic use and available in select countries.
March 2025—Illumina announced a new spatial technology program that the company says will empower researchers to map complex tissues and understand cellular behavior at an unprecedented scale. Enabled on Illumina sequencers and a new multimodal analysis platform, Illumina Connected Multiomics, the spatial technology delivers unbiased whole-transcriptome profiling with cellular resolution and high sensitivity. The technology will allow researchers to examine the spatial proximity of millions of cells per experiment, enabled by a capture area nine times larger than existing technologies and with four times greater resolution. It is compatible with Illumina NextSeq and NovaSeq sequencers.
March 2025—BioMérieux announced that its BioFire FilmArray Gastrointestinal (GI) Panel Mid has obtained FDA clearance. The molecular PCR test is capable of simultaneously detecting 11 pathogens directly from a stool sample from individuals presenting with signs or symptoms of gastrointestinal infection. It runs on the BioFire FilmArray 2.0 and Torch PCR platforms, requires about two minutes of hands-on time, and has an approximate run time of one hour. The panel will be commercially available in the United States at the
March 2025—Qiagen announced that the German Federal Patent Court has ruled in Qiagen’s favor in a patent dispute against SD Biosensor. The court’s decision upholds Qiagen’s intellectual property rights involving the German part of European patent EP 3 421 997, which protects key innovations in tuberculosis detection. Patents covering these innovations have been issued to Qiagen in several other countries, the company said in a press statement, and form part of a group of more than 120 patents currently issued for QuantiFeron.
March 2025—Cision Vision has introduced its InVision imaging system and Vision Board. The technologies aim to enhance the efficiency and accuracy of lymph node dissections at the gross bench.
March 2025—Thermo Fisher Scientific has received FDA 510(k) clearance for the Applied Biosystems TaqPath COVID-19, Flu A, Flu B, RSV Select Panel. The real-time PCR-based multiplex test covers the detection and differentiation of SARS-CoV-2, influenza A and B, and respiratory syncytial virus and enables the detection of co-infection. The panel runs on the Applied Biosystems QuantStudio 5 Dx real-time PCR system.
March 2025—Roche announced that its Elecsys sFlt-1/PlGF ratio for preeclampsia has received FDA 510(k) clearance. The preeclampsia ratio supports the management of pregnant patients who have a singleton pregnancy and is intended to help clinicians stratify hospitalized patients into low- and high-risk categories for developing severe preeclampsia within two weeks of presentation.
